MichalMrugMD

Professor, Medicine, University of Alabama School of Medicine

Dr. Mrug is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1717 6th Ave S
Birmingham, AL 35233
Phone+1 800-822-8816

Fax+1 205-933-4497

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

PubMed

23 citations
Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology–Polycystic Kidney Disease (SONG-PKD...
Yeoungjee Cho, Allison Tong, Jonathan C. Craig, Reem A. Mustafa, Arlene B. Chapman
American Journal of Kidney Diseases. 2021-02-01
123 citations
Ketosis ameliorates renal cyst growth in polycystic kidney disease
Jacob A. Torres, Samantha L Kruger, Caroline Broderick, Tselmeg Amarlkhagva, Shagun Agrawal
Cell Metabolism. 2019-12-03
14 citations
Sodium and potassium excretion predict increased depression in urban adolescents.
Sylvie Mrug, Catheryn A. Orihuela, Michal Mrug, Paul W. Sanders
Physiological Reports. 2019-08-01

Journal Articles

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Ronald D Perrone, Anjay Rastogi, Terry Watnick, Arlene B Chapman, Michal Mrug, Vicente E Torres, Fouad T Chebib, Neera K Dahl, Peter C Harris, Journal of the American Society of Nephrology

Baseline Total Kidney Volume and the Rate of Kidney Growth Are Associated with Chronic Kidney Disease Progression in Autosomal Dominant Polycystic Kidney DiseaseDecember 2017

Otsuka’s JYNARQUE™ (Tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)April 24th, 2018